查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994516

2026年全球子宫颈人类乳突病毒（HPV）信使核糖核酸（mRNA）检测市场报告

Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，子宫颈人类乳突病毒（HPV）传讯RNA（mRNA）检测市场发展迅速。预计该市场将从2025年的10.6亿美元成长到2026年的12.2亿美元，复合年增长率（CAGR）为14.6%。过去几年成长要素包括子宫颈癌筛检计画的扩展、分子诊断技术在妇科领域的应用、人们对高危险型HPV（HR-HPV）感染风险的认识不断提高、自动化PCR平台的普及以及集中式诊断检查室的扩张。

预计未来几年子宫颈人类乳突病毒 (HPV)传讯RNA(mRNA) 检测市场将快速成长，到 2030 年将达到 21.2 亿美元，复合年增长率 (CAGR) 为 14.9%。预测期内的成长要素包括：HPV筛检的普及、对高特异性癌症风险分层的需求不断增长、基于人群的筛检项目不断扩大、数位病理和报告系统的整合以及对先进诊断技术投资的增加。预测期内的主要趋势包括：基于 mRNA 的子宫颈癌初步筛选筛检方法的广泛应用、全自动分子检测平台的日益普及、基因型特异性反射检测整合的进展、高特异性筛检演算法的改进以及对临床实用 HPV 检测的日益重视。

子宫颈癌发生率的上升预计将加速子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场的扩张。子宫颈癌是一种发生在子宫颈细胞的恶性肿瘤，主要由持续感染高风险型 HPV 引起，并且仍然是全球女性癌症相关疾病和死亡的主要原因之一。子宫颈癌发生率的上升与子宫颈癌筛检计画的参与率低有关，导致筛检延迟，并使持续性 HPV 感染发展为癌症。子宫颈 HPV mRNA 检测有助于早期发现活动性高风险 HPV 感染，改善风险分层，并实现及时干预以延缓疾病进展。例如，根据澳洲政府机构澳洲癌症协会的数据，预计2023年子宫颈癌死亡人数为265人，2025年为254人。因此，子宫颈癌发生率的上升正在推动子宫颈人类乳突病毒mRNA检测市场的成长。

在子宫颈人类乳突病毒 (HPV)传讯RNA(mRNA) 检测市场中，主要企业正致力于开发多重即时PCR即时PCR技术的创新之处在于，它能够在单一 PCR 反应中同时检测和定量多个 HPV E6/E7 mRNA 标靶和高危险型，从而提高子宫颈 HPV 检测的准确性、效率和临床效用。例如，2024 年 7 月，总部位于希腊的诊断试剂製造商 Medicon Hellas SA 作为 Uni-Medica 在希腊和塞浦路斯的独家经销商，推出了用于 HPV E6/E7 mRNA基因型鉴定的多重即时PCR试剂盒。本试剂盒相容于多种PCR仪，包括Bio-Rad CFX96和鸿仕SLAN-96系列，可透过萤光染料分析计算Ct值。除细胞学检体外，还可用于多种检体，例如精液、尿液和肛门拭子，并已获得CE-IVD认证。 2.5小时即可获得结果。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场：吸引力评分与分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 物联网、智慧基础设施、互联生态系统
  • 主要趋势
    • 扩大基于mRNA的子宫颈癌初步筛选筛检的应用
    • 扩大全自动分子检测平台的使用
    • 基因型特异性反射检测的整合正在推进中。
    • 高特异性筛检演算法的扩展
    • 人们对临床实用型HPV检测的兴趣日益浓厚

第五章 终端用户产业市场分析

  • 医院和诊所
  • 诊断检查室
  • 研究机构
  • 公共卫生筛检计划
  • 妇女健康中心

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场规模、比较和成长率分析
  • 全球子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场表现：规模和成长，2020-2025 年
  • 全球子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场预测：规模和成长，2025-2030 年，2035 年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 依产品类型
  • 检测试剂盒、仪器、试剂及耗材
  • 透过使用
  • 子宫颈癌筛检、调查和其他用途
  • 最终用户
  • 医院和诊所、诊断检查室机构和其他最终用户
  • 依类型细分：检测试剂盒
  • 传讯RNA检测试剂盒、多重检测套组、高风险基因型特异性试剂盒、筛检及诊断试剂盒
  • 按类型细分：设备
  • 即时聚合酵素链锁反应（PCR）系统、自动化分子分析仪、样本製备系统、核酸萃取装置。
  • 按类型细分：试剂和耗材
  • 引子和探针、酵素和缓衝液、对照品和标准品、萃取和纯化耗材

第十章 区域与国别分析

  • 全球子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场：按地区划分，实际结果和预测，2020-2025 年、2025-2030 年预测、2035 年预测
  • 全球子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场：按国家/地区划分，实际结果和预测，2020-2025 年、2025-2030 年预测、2035 年预测

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 子宫颈人类乳突病毒（HPV）信使核糖核酸（mRNA）检测市场：竞争格局和市场份额，2024年
  • 子宫颈人类乳突病毒 (HPV) 信使核糖核酸 (mRNA) 检测市场：公司估值矩阵
  • 子宫颈人类乳突病毒（HPV）信使核糖核酸（mRNA）检测市场：公司简介
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • Eurofins Scientific
    • Agilent Technologies Inc.

第37章 其他大型企业和创新企业

  • bioMerieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN NV, Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon SA, AB ANALITICA srl, Arbor Vita Corporation, Mylab Discovery Solutions

第38章：全球市场竞争基准分析与仪錶板

第39章：预计进入市场的Start-Ups

第四十章 重大併购

第41章 具有高市场潜力的国家、细分市场与策略

  • 2030年子宫颈人类乳突病毒（HPV）信使核糖核酸（mRNA）检测市场：提供新机会的国家
  • 2030年子宫颈人类乳突病毒（HPV）信使核糖核酸（mRNA）检测市场：提供新机会的细分市场
  • 2030年子宫颈人类乳突病毒（HPV）信使核糖核酸（mRNA）检测市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第42章附录

简介目录
Product Code: ME5MCHPH01_G26Q1

Cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing is a molecular diagnostic technique that identifies the expression of E6/E7 oncogenic mRNA from high-risk HPV strains in cervical specimens, indicating an active infection that is directly involved in cervical cellular transformation. In contrast to HPV DNA tests that only confirm the presence of viral genetic material, mRNA testing offers greater specificity for clinically relevant infections associated with an increased risk of cervical precancerous lesions and cancer.

The primary product types of cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing include assay kits, instruments, and reagents and consumables. Assay kits refer to ready-to-use kits developed to detect and quantify HPV mRNA for the early diagnosis and screening of cervical cancer. These products are applied across areas including cervical cancer screening, research, and other applications, and are used by end users including hospitals and clinics, diagnostic laboratories, research institutes, and other end users.

Tariffs are impacting the cervical HPV mRNA testing market by increasing costs of imported molecular reagents, enzymes, primers, probes, automated analyzers, and nucleic acid extraction systems used across screening and diagnostic workflows. Diagnostic laboratories and hospital networks in North America and Europe are most affected due to reliance on imported assay kits and instruments, while Asia-Pacific faces pricing pressure on export-oriented diagnostic manufacturing. These tariffs are increasing per-test costs and slowing procurement cycles for public screening programs. However, they are also encouraging local reagent production, regional assay development, and domestic manufacturing of molecular diagnostic platforms, strengthening long-term testing infrastructure resilience.

The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market research report is one of a series of new reports from The Business Research Company that provides cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market statistics, including cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing industry global market size, regional shares, competitors with a cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market share, detailed cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market segments, market trends and opportunities, and any further data you may need to thrive in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing industry. This cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market size has grown rapidly in recent years. It will grow from $1.06 billion in 2025 to $1.22 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing cervical cancer screening program coverage, adoption of molecular diagnostics in gynecology, rising awareness of hr-hpv infection risks, availability of automated pcr platforms, expansion of centralized diagnostic laboratories.

The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market size is expected to see rapid growth in the next few years. It will grow to $2.12 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing shift toward primary hpv screening, growing demand for high-specificity cancer risk stratification, expansion of population-based screening programs, integration of digital pathology and reporting systems, increasing investments in precision diagnostics. Major trends in the forecast period include increasing adoption of mrna-based primary cervical screening assays, growing use of fully automated molecular testing platforms, rising integration of genotype-specific reflex testing, expansion of high-specificity screening algorithms, enhanced focus on clinically actionable hpv detection.

The increasing prevalence of cervical cancer is expected to accelerate the expansion of the cervical human papillomavirus messenger ribonucleic acid testing market going forward. Cervical cancer is a malignant condition that develops in cervical cells, primarily caused by persistent infection with high-risk human papillomavirus types, and remains a major contributor to cancer-related illness and mortality among women globally. The growing prevalence of cervical cancer is linked to low participation in cervical screening programs, resulting in delayed detection and progression of persistent HPV infections into cancer. Cervical human papillomavirus messenger ribonucleic acid testing supports early identification of active high-risk HPV infections, improves risk classification, and enables timely intervention to reduce disease progression. For example, in December 2025, according to Cancer Australia, an Australia-based government agency, there were 265 deaths from cervical cancer in 2023, and it was estimated that there would be 254 deaths in 2025. Therefore, the increasing prevalence of cervical cancer is strengthening the growth of the cervical human papillomavirus messenger ribonucleic acid testing market.

Leading companies operating in the cervical human papillomavirus messenger ribonucleic acid (mRNA) testing market are concentrating on developing technological advancements, such as multiplex real-time PCR innovations, to gain competitive advantage by improving diagnostic accuracy, enabling simultaneous E6/E7 mRNA detection and high-risk HPV genotyping, reducing false positives, lowering testing costs, and expanding adoption. Multiplex real-time PCR innovations refer to the capability to detect and quantify multiple HPV E6/E7 mRNA targets and high-risk genotypes simultaneously in a single PCR reaction, improving accuracy, efficiency, and clinical relevance of cervical HPV testing. For instance, in July 2024, Medicon Hellas S.A., a Greece-based diagnostics company, introduced the multiplex real-time PCR kit for HPV E6/E7 mRNA genotyping as the exclusive distributor for Uni-Medica in Greece and Cyprus. The kit features compatibility with multiple PCR instruments such as Bio-Rad CFX96 and Hongshi SLAN-96 series for fluorochrome analysis with Ct values, applicability to diverse samples including semen, urine, and anal swabs beyond cytology, and CE-IVD marking with results available in 2.5 hours.

In April 2025, Institut Pasteur, a France-based organization focused on biomedical research, translational science, and infectious disease innovation, partnered with ABL Diagnostics. The objective of this partnership is to commercialize and scale advanced HPV RNA sequencing technology by integrating Institut Pasteur's HPV RNA-seq intellectual property into ABL Diagnostics' molecular diagnostic portfolio, thereby strengthening technological expertise and expanding high-risk HPV diagnostic offerings. ABL Diagnostics is a France-based provider of molecular diagnostic solutions, specializing in viral load testing, infectious disease assays, and advanced RNA-based diagnostic technologies for clinical and public health use.

Major companies operating in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Eurofins Scientific, Agilent Technologies Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN N.V., Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon S.A., AB ANALITICA s.r.l., Arbor Vita Corporation, Mylab Discovery Solutions, Guangdong Hybribio Biotech Co. Ltd., Atila Biosystems, GeneFirst Ltd., Advanced Molecular Diagnostics.

North America was the largest region in the cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cervical human papillomavirus (HPV) messenger ribonucleic acid (mRNA) testing market consists of sales of molecular diagnostic products, primary cervical screening assays, genotyping add-ons, fully automated platform assays, laboratory-developed tests, experimental kits, and integrated screening panels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cervical human papillomavirus (hpv) messenger ribonucleic acid (mrna) testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product Type: Assay Kits; Instruments; Reagents And Consumables
  • 2) By Application: Cervical Cancer Screening; Research; Other Applications
  • 3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
  • Subsegments:
  • 1) By Assay Kits: Messenger Ribonucleic Acid Detection Kits; Multiplex Testing Kits; High Risk Genotype Specific Kits; Screening And Diagnostic Kits
  • 2) By Instruments: Real Time Polymerase Chain Reaction Systems; Automated Molecular Analyzers; Sample Preparation Systems; Nucleic Acid Extraction Instruments
  • 3) By Reagents And Consumables: Primers And Probes; Enzymes And Buffers; Controls And Standards; Extraction And Purification Consumables
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Becton; Dickinson and Company; Eurofins Scientific; Agilent Technologies Inc.; bioMerieux SA; Bio-Rad Laboratories Inc.; Bio-Techne Corporation; Co-Dx Ltd.; Promega Corporation; Seegene Inc.; Molbio Diagnostics; QIAGEN N.V.; Sansure Biotech Inc.; Xiamen Zeesan Biotech Co. Ltd.; DiaCarta Inc.; Operon S.A.; AB ANALITICA s.r.l.; Arbor Vita Corporation; Mylab Discovery Solutions; Guangdong Hybribio Biotech Co. Ltd.; Atila Biosystems; GeneFirst Ltd.; Advanced Molecular Diagnostics.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Mrna-Based Primary Cervical Screening Assays
    • 4.2.2 Growing Use Of Fully Automated Molecular Testing Platforms
    • 4.2.3 Rising Integration Of Genotype-Specific Reflex Testing
    • 4.2.4 Expansion Of High-Specificity Screening Algorithms
    • 4.2.5 Enhanced Focus On Clinically Actionable Hpv Detection

5. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Analysis Of End Use Industries

  • 5.1 Hospitals And Clinics
  • 5.2 Diagnostic Laboratories
  • 5.3 Research Institutes
  • 5.4 Public Health Screening Programs
  • 5.5 Women'S Health Centers

6. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Segmentation

  • 9.1. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Assay Kits, Instruments, Reagents And Consumables
  • 9.2. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cervical Cancer Screening, Research, Other Applications
  • 9.3. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
  • 9.4. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Sub-Segmentation Of Assay Kits, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Messenger Ribonucleic Acid Detection Kits, Multiplex Testing Kits, High Risk Genotype Specific Kits, Screening And Diagnostic Kits
  • 9.5. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Real Time Polymerase Chain Reaction Systems, Automated Molecular Analyzers, Sample Preparation Systems, Nucleic Acid Extraction Instruments
  • 9.6. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Sub-Segmentation Of Reagents And Consumables, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Primers And Probes, Enzymes And Buffers, Controls And Standards, Extraction And Purification Consumables

10. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Regional And Country Analysis

  • 10.1. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 11.1. Asia-Pacific Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 12.1. China Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 13.1. India Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 14.1. Japan Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 15.1. Australia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 16.1. Indonesia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 17.1. South Korea Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 18.1. Taiwan Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 19.1. South East Asia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 20.1. Western Europe Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 21.1. UK Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 22.1. Germany Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 23.1. France Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 24.1. Italy Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 25.1. Spain Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 26.1. Eastern Europe Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 27.1. Russia Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 28.1. North America Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 29.1. USA Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 30.1. Canada Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 31.1. South America Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 32.1. Brazil Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 33.1. Middle East Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

  • 34.1. Africa Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market, Segmentation By Product Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Regulatory and Investment Landscape

36. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Competitive Landscape And Company Profiles

  • 36.1. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Company Profiles
    • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Becton, Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Other Major And Innovative Companies

  • bioMerieux SA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Co-Dx Ltd., Promega Corporation, Seegene Inc., Molbio Diagnostics, QIAGEN N.V., Sansure Biotech Inc., Xiamen Zeesan Biotech Co. Ltd., DiaCarta Inc., Operon S.A., AB ANALITICA s.r.l., Arbor Vita Corporation, Mylab Discovery Solutions

38. Global Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market

41. Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market High Potential Countries, Segments and Strategies

  • 41.1 Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Cervical Human Papillomavirus (HPV) Messenger Ribonucleic Acid (mRNA) Testing Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer